Guangzhou Baiyunshan Pharmaceutical Holdings Company Stock Forecast for 2023 - 2025 - 2030
Updated on 05/03/2024
Guangzhou Baiyunshan Pharmaceutical Holdings Company Stock Forecast and Price Target
The average price target of HK$22.85 for Guangzhou Baiyunshan Pharmaceutical Holdings Company's stock set by distinguished analysts in recent weeks would represent a potential upside of approximately 4.34% from the last closing price in May, 2024 if reached by the end of the year. This potential increase is based on a high estimate of HK$24.10 and a low estimate of HK$18.59. If you're considering investing in 874 stock, it's important to look at its competitors too.
4.34% Upside
Guangzhou Baiyunshan Pharmaceutical Holdings Company Fair Value Forecast for 2023 - 2025 - 2030
In the last two years, Guangzhou Baiyunshan Pharmaceutical Holdings Company's Price has gone down from HK$25.33 to HK$0.00 – a 100.00% drop. For next year, analysts predict Fair Value of HK$33.32, which would mean an increase of 100.00%. Over the next seven years, experts predict that Guangzhou Baiyunshan Pharmaceutical Holdings Company's Fair Value will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 600276 Stock Forecast | Jiangsu Hengrui Medicine | Buy |
15
|
¥46.16 | Buy/Sell | ¥56.49 | 16.98% |
| BAYN Stock Forecast | Bayer | Hold |
5
|
28.13€ | Buy/Sell | 45.15€ | 6.65% |
| 000538 Stock Forecast | Yunnan Baiyao Group Co.,Ltd | Outperform |
18
|
¥57.25 | Buy/Sell | ¥65.39 | 11.79% |
| 601607 Stock Forecast | Shanghai Pharmaceuticals Holdi... | Outperform |
18
|
¥17.92 | Buy/Sell | ¥20.67 | 22.77% |
| 000999 Stock Forecast | China Resources Sanjiu Medical... | Buy |
18
|
¥59.97 | Buy/Sell | ¥65.95 | 13.62% |
Guangzhou Baiyunshan Pharmaceutical Holdings Company Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Guangzhou Baiyunshan Pharmaceutical Holdings Company's Revenue has grown by 22.44%, rising from HK$61.67B to HK$75.52B. In the next year, 0 analysts estimate that Guangzhou Baiyunshan Pharmaceutical Holdings Company's Revenue will decrease by 6.47%, reaching HK$70.63B. According to professional forecasts, in 2030, Guangzhou Baiyunshan Pharmaceutical Holdings Company's Revenue will decrease by 6.04%, reaching HK$70.95B.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 000963 Stock Forecast | Huadong Medicine | Buy |
18
|
¥32.94 | Buy/Sell | ¥52.40 | 34.34% |
| 600196 Stock Forecast | Shanghai Fosun Pharmaceutical ... | Outperform |
16
|
¥23.67 | Buy/Sell | ¥33.57 | 20.83% |
| 002422 Stock Forecast | Sichuan Kelun Pharmaceutical | Outperform |
16
|
¥33.95 | Buy/Sell | ¥37.90 | 23.33% |
.jpg)
Guangzhou Baiyunshan Pharmaceutical Holdings Company Dividend per Share Forecast for 2023 - 2025 - 2030
In the last three years, Guangzhou Baiyunshan Pharmaceutical Holdings Company's Dividend per Share has grown, rising from HK$0.54 to HK$0.75 – a growth of 38.89%. In the next year, analysts believe that Dividend per Share will reach HK$0.80 – an increase of 6.67%. Professionals believe that By 2030, Guangzhou Baiyunshan Pharmaceutical Holdings Company's Dividend per Share will fall to HK$0.75 – a 0.10% decrease from its current value.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 600079 Stock Forecast | Humanwell Healthcare (Group) | Buy |
0
|
¥20.25 | Buy/Sell | ¥32.49 | -100.00% |
| 000513 Stock Forecast | Livzon Pharmaceutical Group | Outperform |
18
|
¥36.98 | Buy/Sell | ¥39.23 | 11.41% |
| 600750 Stock Forecast | Jiang Zhong Pharmaceutical Co.... | - |
18
|
¥22.77 | Buy/Sell | ¥15.25 | -100.00% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 600812 Stock Forecast | North China Pharmaceutical Com... | - |
12
|
¥5.18 | Buy/Sell | ¥12.26 | -100.00% |
| 600664 Stock Forecast | Harbin Pharmaceutical Group | - |
11
|
¥2.80 | Buy/Sell | ¥0.00 | -100.00% |
| UPC Stock Forecast | Universe Pharmaceuticals INC | - |
0
|
$2.17 | Buy/Sell | $0.00 | -100.00% |
Guangzhou Baiyunshan Pharmaceutical Holdings Company EBITDA Forecast for 2023 - 2025 - 2030
Guangzhou Baiyunshan Pharmaceutical Holdings Company's EBITDA has seen impressive growth In the last three years, rising from HK$3.37B to HK$5.16B – a growth of 53.18%. In the next year, analysts believe that EBITDA will reach HK$5.98B – an increase of 15.87%. For the next seven years, the forecast is for EBITDA to grow by 14.65%.
Guangzhou Baiyunshan Pharmaceutical Holdings Company EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Guangzhou Baiyunshan Pharmaceutical Holdings Company's EBIT has grown by 50.75%, rising from HK$3.02B to HK$4.55B. For the next year, analysts predict that EBIT will reach HK$5.27B – an increase of 15.91%. Over the next seven years, experts believe that Guangzhou Baiyunshan Pharmaceutical Holdings Company's EBIT will grow at a rate of 18.17%.
Guangzhou Baiyunshan Pharmaceutical Holdings Company EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last two years, Guangzhou Baiyunshan Pharmaceutical Holdings Company's EPS has gone down from HK$2.03 to HK$0.00 – a 100.00% drop. For next year, analysts predict EPS of HK$2.67, which would mean an increase of 100.00%. Over the next seven years, experts predict that Guangzhou Baiyunshan Pharmaceutical Holdings Company's EPS will grow at a rate of 100.00%.
Site Navigation
.jpg)